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Abstract
Osteocytes are differentiated osteoblasts that become surrounded by matrix during the process of 
bone formation. The acquisition of the osteocyte phenotype is achieved by profound modifications 
in gene expression that confer adaptation to the changing cellular functions and constitute the 
molecular signature of osteocytes. The levels of expression of genes characteristic of osteoblasts is 
altered; and the expression of genes/proteins that impart dendritic cellular morphology, regulate 
matrix mineralization, and control the function of bone surface cells, is orderly modulated during 
osteocytogenesis. The discovery of human mutations of osteocytic genes had contributed to a large 
extent to reveal the role of osteocytes in bone homeostasis. Osteocytes are targets of mechanical 
force imposed to the skeleton and also play a critical role in integrating mechanosensory pathways 
with the action of hormones, thereby leading to the orchestrated response of bone to environmental 
cues. Current, novel therapeutic approaches harness this accumulating knowledge by targeting 
osteocytic signaling pathways and messengers to improve skeletal health.
OLD THEORIES AND NEW EVIDENCE FOR A CENTRAL ROLE OF 
OSTEOCYTES IN BONE HOMEOSTASIS
Osteocytes, the most abundant bone cells, are essential for the accomplishment of the 
functions of the skeleton. Far from being inactive quiescent cells buried in the mineralized 
tissue (Figure 1), osteocytes coordinate bone acquisition during growth and the maintenance 
of a healthy skeleton suit for locomotion and protection of essential organs. Osteocytes 
orchestrate the work of osteoblasts that form bone and osteoclasts that resorb it by producing 
and secreting factors, thus adapting the skeleton to mechanical needs and hormonal changes. 
Osteocytes contribute to the endocrine functions of bone by secreting hormones that affect 
other tissues; and they also regulate mineral homeostasis and hematopoiesis, which are 
essential for organismal life. The central role of osteocytes was long envisioned by pioneers 
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in the field, who proposed potential mechanisms by which these cells could contribute to the 
functions of the skeleton, well before such mechanisms were unraveled.
Marotti and colleagues showed by microscopic examination of human bone that osteocytes 
within lacunae extent multiple cytoplasmic projections reaching neighboring osteocytes and 
cells on bone surfaces.1 They proposed that osteocytes are central players in this cellular 
network in which cells are connected via gap junctions and are able to sense mechanical and 
biochemical signals.2 Because osteocytes exhibit longer and more abundant dendrites facing 
the bone surface than the mineralized bone and the number of osteocytic dendrites in contact 
with osteoblasts was inversely proportional to the osteoblast size (and thus activity), they 
proposed that osteocytes send inhibitor signals to osteoblasts to slow bone formation.2 Based 
on this theory, Martin developed a mathematical model that predicts that during the refilling 
of resorption cavities there is an initial increase in bone formation followed by a reduction in 
osteoblast activity as osteocytes mature.3 This model also predicts that the osteoblasts most 
affected by osteocytic inhibitory signals have higher probability to be buried within the 
matrix still being synthesized by neighboring osteoblasts, thus becoming the next population 
of osteocytes. Today, the importance of the osteocyte network and the mechanisms and 
messengers by which osteocytes control not only bone formation, but also resorption and 
hematopoiesis, are recognized and some of the molecular mediators have been identified.
Frost in pioneer studies demonstrated decreased osteocyte viability with age,4 proposed that 
osteocytes regulate water and calcium flow from the canaliculi to the blood compartment,5 
and developed the mechanostat theory that proposes that the magnitude of the mechanical 
stimulation applied to bone dictates whether bone will be increased (by increasing bone 
formation) or reduced (by increasing bone resorption).6 In this model, osteocytes sense the 
load imposed to bone and respond by signaling to osteoblasts and osteoclasts to adapt to 
mechanical changes.7 We now know that one of the osteocyte-derived molecules involved in 
bone adaptation is Sost/sclerostin.8, 9
Seminal work by Parfitt in the 1970s postulated that osteocytes are involved in the response 
of the skeleton to parathyroid hormone (PTH).10 Based on the rapid timing of hypercalcemic 
responses to PTH, the fact that new protein synthesis is not required, and that calcium is 
released into the circulation at two different rates, Parfitt concluded that osteocytes control 
the rapid release of calcium, whereas osteoclasts and resorption determines the later phase of 
calcium released from bone to the circulation induced by PTH. Studies using genetically 
modified mice have recently demonstrated profound skeletal effects of activation of the PTH 
receptor in osteocytes11–14 and defective response to PTH of mice lacking this receptor in 
osteocytes (15 and Bellido et al, unpublished). These studies support and extend Parfitt’s 
concept that indeed osteocytes are target cells of PTH action. Further, mice lacking the PTH 
receptor in osteocytes lose less bone with lactation, a condition in which calcium release 
from the skeleton to the blood induced by PTHrP (the other ligand of the PTH receptor) is 
required for milk production in the mammary glands.16 In addition, the characteristic 
increase in osteocyte lacunar size observed in lactating wild type mice is not found mice 
lacking the PTH receptor in osteocytes, suggesting that removal of perilacunar bone by 
osteocytes is a source of calcium and contributes to the bone loss. The process of perilacunar 
remodeling, named earlier by Belanger osteocytic osteolysis,17 is achieved by the expression 
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by osteocytes of genes usually expressed by osteoclasts during bone resorption. These genes 
encode for proteins that decrease extracellular pH such as carbonic anhydrases and ATPases, 
degrade the extracellular matrix as MMP13 and cathepsin K, or dissolve the mineral as 
TRAPase.
Thus, the molecular mechanisms by which osteocytes accomplish the functions postulated 
by pioneers of the field are being unraveled and it is expected that current research will 
continue to increase our knowledge of osteocyte biology and pathophysiology.
MOLECULAR AND FUNCTIONAL SIGNATURE OF OSTEOCYTES
An estimated 5–20% of the osteoblasts present on the bone surface become surrounded by 
matrix proteins that they produce, and differentiate into osteocytes.18,19 The mechanism why 
which some osteoblasts and not others undergo this process is uncertain. Nevertheless, this 
transition is characterized by alterations in gene expression and it is accompanied by 
morphological and functional changes. The highly secretory osteoblasts are characterized by 
their cuboidal shape with large nucleus located close to the cell basal membrane, enlarged 
Golgi apparatus on the nuclear apical surface, and extensive endoplasmic reticulum. During 
osteocytogenesis, the number of organelles markedly reduces and the ratio between nuclear 
and cytoplasm volume increases as the cell acquires a star-like morphology (Figure 1). The 
long cytoplasmic processes exhibited by osteocytes run through canaliculi dig in mineralized 
bone and touch neighboring osteocytes, bone surface cells, and endothelial cells of the blood 
vessels. This extensive lacunar-canalicular system is maintained by the ability of osteocytes 
themselves of remodeling their surrounding space, as demonstrated by calcification of the 
lacuna and reduced numbers of canaliculi when osteocytes are lost by apoptosis. The 
osteocyte lacunar-canalicular system also distributes molecules secreted by osteocytes 
among all cells of the bone-bone marrow.
The genes that are regulated during osteocyte development and maturation can be classified 
based on their function in four main categories: 1) genes related to dendritic morphology 
and canaliculi formation that facilitate cell embedding into the bone matrix; 2) genes related 
to phosphate metabolism and matrix mineralization; 3) genes that regulate bone formation; 
and 4) genes that regulate bone resorption (Figure 2).
Genes related to formation and maintenance of the osteocytic network
The transition from osteoblasts to osteocytes occurs while the cells become surrounded first 
by un-mineralized matrix or osteoid, and later, by mineralized bone matrix. Several 
molecules have been identified as mediators of the development of dendrites by dictating the 
formation of osteocytic projections or, indirectly, by controlling mineralization and matrix 
degradation and thus the proper formation of the lacunar-canaliculi system.
E11 was originally described in osteoblastic cells treated by phorbol ester and named 
OTS-8,20, 21 and subsequently cloned from other tissues and named podoplanin, gp38, or 
T1α. E11 is expressed in dendritic cells of the kidney, lung, brain, and skin.22, 23 In bone, 
E11 is expressed in newly embedded osteocytes, but not in more mature cells deep in the 
bone matrix or in osteoblasts on the bone surface, indicating that is a marker of early 
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osteocyte differentiation.24 E11 expression is required for dendrite elongation induced by 
loading in vitro and it is increased by mechanical stimulation in vitro and in vivo, suggesting 
that mechanical signals might control osteocytogenesis.
E11 binds to CD44, a molecule also expressed in neuronal dendrites,25 and expression of 
either molecule has been associated with osteocytic dendrite branching.26, 27 Osteocytic 
dendrites also contain α-actinin and fimbrin, actin-bundling proteins required for the 
cytoskeletal organization of osteocytes isolated from chicken.28, 29 Remarkably, mutations 
of PLS3, the human homolog of fimbrin that encodes for the protein Plastin 3, causes X-
linked osteoporosis with fractures,30 suggesting an association of deficient dendrite 
formation with bone fragility.
Dentin matrix protein 1 (DMP1) is expressed in mature osteoblasts and its expression 
increases as osteoblasts differentiate towards osteocytes.31 DMP1 expression is required for 
proper osteocyte maturation. This is evidenced by abnormally elevated expression of 
osteoblastic and early osteocytic genes (such as alkaline phosphatase, collagen type 1 and 
E11) and low expression of sclerostin (a marker of mature osteocytes) in deeply embedded 
osteocytes in mice lacking the DMP1 gene.32 Further, mineralization is defective in these 
mice, likely causing the incomplete differentiation of osteocytes as well as the disorganized 
osteocytic lacunar-canalicular system. Thus the defective osteocyte maturation and the 
abnormal morphology of osteocytes in DMP1-null mice can be corrected by normalizing 
phosphate levels using anti-FGF23 antibodies33 or by improving bone mineralization with 
anti-sclerostin antibodies.34
As DMP1, the expression of matrix metalloproteinases (MMPs) also increases as osteoblasts 
differentiate into osteocytes. The function of MMPs in osteocytogenesis might be related to 
their ability to cleave collagen in the matrix surrounding osteocytes, allowing the formation 
of canaliculi through which osteocytes extend cytoplasmic projections. Consistent with this 
notion, mice lacking MMP14, a member of the MMP family of proteins, exhibit reduced or 
absent osteocytic processes.35 Further, the ability of collagen to be degraded by MMP13 is 
required to maintain osteocyte viability, as demonstrated by increased osteocyte apoptosis in 
mice expressing a mutated non-degradable collagen1.36
A molecule crucial for the functionality of the osteocyte network is connexin 43 (Cx43), the 
most abundant member of the connexin family of proteins expressed in osteocytes.37 Cx43 
forms gap junction channels between cells participating in cell-to-cell communication within 
the osteocyte network; and it also forms hemichannels connecting cells with the extracellular 
milieu. Deletion of the Cx43 gene from osteocytes in mice decreases osteocyte viability and 
induces changes in the geometry of long bones, which present the features of bones from old 
mice or humans.38–40 Apoptotic osteocytes and empty lacunae are increased, the bone 
marrow cavity is enlarged by exaggerated endosteal resorption, and the diameter of the 
bones is larger due to increased periosteal bone apposition. These effects of Cx43 deletion 
are intrinsic to osteocytes, as knockdown of the gene in vitro render cells that die 
spontaneously and exhibit increased RANKL/OPG ratio and ability to support osteoclast 
formation.40, 41 Further, osteoclasts are found on surfaces adjacent to areas where apoptotic 
osteocytes accumulate in Cx43 knockout mice, suggesting that signals released by dying 
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osteocytes are required to target osteoclast recruitment. Cx43 expression in osteoblasts/
osteocytes is also required for cell survival induced by bisphosphonates or PTH as well as 
for full bone anabolism in response to PTH.42–45 Cx43 is also involved in the response of 
osteocytes to mechanical signals. However, whereas PGE2 release induced by in vitro 
mechanical stimulation requires Cx43 expression in osteocytes, paradoxically Cx43 restrains 
the response of bone to mechanical stimulation in vivo as deletion of the Cx43 gene from 
osteocytes enhances the anabolic response of bone to loading.46–48
Osteocytic genes related to phosphate metabolism and matrix mineralization
A feature of the process of osteocyte differentiation is the increase in expression of genes 
related with phosphate metabolism and matrix mineralization.31 These genes encode for 
fibroblast growth factor 23 (FGF23), the members of short integrin-binding ligand-
interacting glycoprotein (SIBLING) family of proteins DMP1 and matrix extracellular 
phosphoglycoprotein (MEPE), phosphate-regulating gene with homologies to 
endopeptidases on the X-chromosome (Phex), and fetuin-A (Figure 2 and 3).31, 49
FGF23 is produced by osteocytes and regulate phosphate metabolism by acting in the 
kidney. FGF23 binds to FGF receptors and the Klotho co-receptor in the renal proximal 
tubule leading to inhibition of renal phosphate reabsorption.50 Deletion of FGF23 in mice 
leads to hyperphosphatemia, decreased bone mineral density, deficient bone formation, and 
accumulation of unmineralized osteoid.51 FGF23 might also act in an auto/paracrine manner 
in osteocytes and other bone cells, as receptors for FGF23 (FGFR1 and Klotho) are also 
expressed in these cells, and could mediate FGF23 functions dependent as well as 
independent of its co-receptor Klotho.13, 52 Thus, deletion of the renal Na/Pi co-transporter 
NaPi2a reverses the hyperphosphatemia but not the defective mineralization of mice lacking 
FGF23, 52 suggesting a direct effect of FGF23 on bone cells. In addition, we have shown 
that the FGF23 co-receptor Klotho is expressed in bone cells in vivo in long bones and 
calvaria at the protein and mRNA levels, as well as in isolated osteoblasts and osteocytes.13 
Furthermore, the levels of FGF23 are increased in mice with active parathyroid hormone 
(PTH) receptor signaling in osteocytes (DMP1-caPTHR1 mice), and this leads to increased 
levels of FGFR1, GALNT3 as well as downstream targets of FGF23 signaling in osteocytes 
from DMP1-caPTHR1 mice, adding support for a direct effect of FGF23 in bone.
Other osteocyte produced molecules regulate FGF23 expression and/or function, thus 
indirectly affecting phosphate homeostasis. For example, human inactivating mutations of 
DMP1 or Phex result in high FGF23 levels and hypophosphatemia.53 Because reducing 
FGF23 and correcting the hypophosphatemia rescue only partially the osteomalacia, it is 
likely that the defective bone mineralization observed in these diseases results from a 
combination of FGF23-mediated effects in the kidney and direct action of DMP1 and Phex 
in bone. Further, studies in animal models and humans showed that altered levels of FGF23, 
Phex, DMP1, and MEPE are associated with impaired glucose metabolism likely by 
decreasing undercarboxylated osteocalcin.54 Therefore, this group of osteocyte-derived 
genes directly or indirectly modulates the homeostasis of bone, kidney and other tissues/
organs.
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As discussed above, DMP1 is required for proper bone mineralization, whereas MEPE is a 
mineralization inhibitor and its deletion from the mouse genome results in increased bone 
mineral density55 (Figure 2 and 3). DMP1 and MEPE expression is upregulated by loading 
and these proteins might be responsible for the local effects of mechanical stimulation in the 
matrix surrounding osteocytes.56
Enzymatic degradation of MEPE generates an acidic serine aspartate-rich MEPE-associated 
(ASARM) peptide that blocks mineralization in vitro and in vivo.57 Phex is a 
metalloendopeptidase that binds to MEPE and its ASARM peptide. Phex deletion in mice 
results in osteomalacia and abnormal osteocytic lacuna-canalicular system.58
The liver protein fetuin-A is an inhibitor of bone mineralization and ectopic calcification, 
which is also expressed in bone and it is enriched in osteocytes compared to osteoblasts.49 
Fetuin-A might be involved in the formation of cellular processes by slowing calcification of 
the matrix that surrounds developing osteocytes.
The regulation of phosphate metabolism appears to result from highly interrelated functions 
of all these osteocytic proteins, as changes in the levels of expression of one of these 
molecules alters the expression of others, constituting a cascade that ultimately regulate 
bone mineralization (Figure 3). Some examples of this interplay are the high levels of 
FGF23 exhibited in humans in the absence of DMP1 and Phex function,53 the decrease in 
active FGF23 levels due to Phex binding to DMP1, the reversal of the hypophosphatemia of 
Phex-deficient mice by FGF23 deletion,51 and the increase in fetuin-A expression in 
osteocytes by an autocrine function of FGF23.49 Altered expression of some of the 
osteocytic genes described above causes disorders of phosphate homeostasis in humans.53 
Excess production of FGF23 or gain-of-function mutations of this hormone results in 
hypophosphatemia, renal phosphate wasting, low vitamin D3 levels and vitamin D-resistant 
rickets, a condition known as autosomal dominant hypophosphatemic rickets (ADHR). 
Increased FGF23 is found in chronic kidney disease (CKD) and is associated with higher 
risk of cardiovascular disease and death. The high levels of FGF23 in late stages of CKD are 
partially due to increased PTH, as evidenced by the reduction in serum FGF23 following 
parathyroidectomy in animal models and patients with CKD. FGF23 was found increased in 
the circulation of a patient with Jansen’s metaphyseal chondrodysplasia, characterized by 
expression of a constitutively active PTH receptor 1 (PTHR1).59 Similarly, mice expressing 
the same PTHR1 mutant in osteocytes exhibit increased expression of FGF23.13 These 
findings demonstrate that some of the actions of PTH in controlling mineral metabolism are 
mediated through regulation of osteocyte-derived FGF23.
Other forms of hypophosphatemia resulting from changes in osteocytic genes are X-linked 
hypophosphatemic rickets (XLH) due to inactivating mutations of the Phex gene and 
autosomal recessive hypophosphatemic rickets (ARHR) due to inactivating mutations of 
DMP1.53
Osteocytic genes that regulate bone formation
One of the most important events of the last 2 decades that advanced our understanding of 
skeletal biology was the discovery of the role of Wnt/βcatenin signaling in bone.60 The so-
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called canonical Wnt signaling pathway controls fate of mesenchymal stem cells (MSC) and 
their differentiation into the various cell lineages. Canonical Wnt signaling restrains 
chondrogenic and adipogenic differentiation while enhances osteoblastic differentiation 
from MSC. In addition, Wnt/βcatenin signalling promotes osteoblast maturation and 
survival of osteoblasts and osteocytes, and inhibits osteoclastogenesis, although indirectly by 
increasing the expression of OPG in osteoblasts and osteocytes.
Osteocytes are critical players in the regulation of this signaling pathway both as targets of 
the Wnt ligands and as producers of molecules that modulate their action. Wnt/βcatenin 
signaling is activated by binding of Wnt proteins to a receptor complex composed of frizzled 
receptors and co-receptors of the low density lipoprotein receptor-related protein (LRP) 
family, LRP5 and 6. This event stabilizes βcatenin, induces its translocation to the nucleus, 
and activates gene transcription. Activation of this pathway is critical for bone acquisition 
and maintenance through increased bone formation and decreased resorption.
Dickkopf-related protein 1 (Dkk1) is a Wnt antagonist expressed in osteoblasts and at higher 
levels in osteocytes.61 Dkk1 binds to LRP5/6 preventing the binding of Wnt ligands. Mice 
overexpressing Dkk1 in osteoblastic cells exhibit decreased bone formation and low bone 
mass, consistent with the stimulatory role of the Wnt/βcatenin pathway on bone formation 
(Figure 4).62 Another Wnt inhibitor, secreted frizzle-related protein 1 (sFRP1) is expressed 
in early osteocytes and its levels decrease as osteocytes mature.63 Consistent with the role of 
sFRP1 as an inhibitor of anabolic Wnt/βcatenin signaling, its deletion from the mouse 
genome results in increased bone mass.60
Another antagonist of Wnt signaling is sclerostin, a protein encoded by the Sost gene, which 
is primarily expressed by mature osteocytes but not by early osteocytes or osteoblasts.64 
Sclerostin binds to the Wnt co-receptors LRP5/6 antagonizing downstream signalling.65 
Sclerostin also binds to LRP4, another member of the LRP family of proteins, which acts as 
a chaperone and is required for the inhibitory action of sclerostin on Wnt/βcatenin signaling.
66
 Absence of sclerostin expression or secretion in humans causes sclerosteosis, van Buchem 
disease, or craniodiaphyseal dysplasia, inherited high bone mass conditions characterized by 
exaggerated bone formation.60 Further, inactivating mutations of the Wnt co-receptor LRP5 
result in low bone mass (osteoporosis pseudoglioma); and, conversely, activating LRP5 
mutations lead to high bone mass partially due to decreased binding affinity of the mutated 
LRP5 for sclerostin. Consistent with the requirement of LRP4 for the inhibitory function of 
sclerostin, individuals with LRP4 inactivating mutations exhibit high bone mass. Moreover, 
deletion of the Sost or LRP4 genes in mice or neutralizing antibodies for sclerostin or LRP4 
reproduces the high bone mass phenotype found in humans lacking Sost or LRP4 activity,
67–71
 whereas overexpression of Sost/sclerostin decreases bone mass.9, 12, 72, 73 Remarkably, 
osteocyte-targeted deletion of LRP5 or overexpression of high bone mass LRP5 mutants 
only in osteocytes reproduces the low or high bone mass, respectively, exhibited by mice or 
humans with the genetic modifications in all cells, suggesting that activation of the pathway 
in osteocytes is sufficient to elicit bone formation downstream of LRP5.74, 75 This 
conclusion is consistent with recent findings demonstrating that osteocytes mediate the 
anabolic actions of canonical Wnt/βcatenin signaling in bone.76
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Osteocalcin, the most abundant non-collagenous protein present in bone, is an inhibitor of 
bone formation, as evidenced by the high bone mass in the absence of defective bone 
mineralization or bone resorption in mice lacking the osteocalcin gene.77 Osteocytes are 
more abundant than osteoblasts, and studies in mice showed that osteocalcin is expressed at 
a higher level by osteocytes;78 therefore, it is tempting to speculate that osteocytes as well as 
osteoblasts contribute to the pool of osteocalcin in the circulation. However, the chief 
cellular source of this hormone is not known. Studies in mice showed that, in addition to its 
role in bone, osteocalcin in its undercarboxylated form can regulate insulin production/
secretion by pancreatic β cells, insulin sensitivity and glucose uptake in muscle, and fat 
metabolism.79 In addition, osteocalcin might regulate testosterone production80 and brain 
development and brain function.81 However, the extra-skeletal role of osteocalcin as a 
molecule with endocrine properties remains controversial and additional studies are required 
to determine the relevance of the purported extra-skeletal functions of osteocalcin in humans 
both under physiological and pathological conditions.
Osteocytic genes that regulate bone resorption and the role of osteocyte apoptosis
Osteocytes produce cytokines that regulate osteoclast formation and survival (Figure 4). 
Osteoclastogenesis involves activation of the receptor activator of nuclear factor κ B 
(RANK) in osteoclast precursors induced by RANK ligand (RANKL) produced by stromal/
osteoblastic cells as well as by osteocytes.31 Osteocytes also secrete the RANKL decoy 
receptor osteoprotegerin (OPG), which binds RANKL competing with RANK and thus 
inhibiting osteoclast differentiation. Studies using genetically modified mice showed that 
deletion of the RANKL gene from osteocytes renders an osteopetrotic phenotype, due to 
reduced number of osteoclasts, decreased resorption, and progressive increase in bone mass,
82, 83
 suggesting that osteocytes are an important source of RANKL in bone.
Macrophage colony stimulating factor (M-CSF), produced by bone cells including 
osteocytes,61 promotes osteoclast precursor proliferation and survival and is required for 
osteoclast formation.84 Similar to mice lacking M-CSF in all tissues,85 mice lacking M-CSF 
only from osteocytes exhibit reduced osteoclast number and osteopetrosis demonstrating the 
osteocytes are an important source of the cytokine in bone.86 Osteocytes also express 
receptors for M-CSF,61 and mice lacking osteocytic M-CSF have osteocytes with abnormal 
morphology, high prevalence of apoptosis, increased ROS production, and reduced gap 
junction communication.86 These findings suggest that osteocytes are not only an important 
source of M-CSF, but also a target cell for this cytokine, which controls osteocyte viability.
The anti-osteoclastogenic cytokine OPG is expressed in both osteoblasts and osteocytes, and 
OPG mRNA expression is more abundant in osteocytes than in osteoblasts isolated by serial 
digestions of bones from 6-week-old mice and at least as abundant in cells from 4-month-old 
mice.87 Moreover, OPG is a target gene of canonical Wnt signaling and mice lacking 
βcatenin from osteoblasts/osteocytes or only from osteocytes exhibit similar reduced OPG 
expression, increased osteoclasts and low bone mass.87–89 These findings suggest that the 
regulation of osteocytic OPG by Wnt/βcatenin signaling plays an important role in the 
control of bone resorption.
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Osteocyte viability is an important component of the cascade of events that directs 
osteoclasts to particular bone surfaces, so-called targeted bone remodeling.90–92 
Accumulation of apoptotic osteocytes in certain areas of bone promotes pre-osteoclast 
recruitment, local osteoclast differentiation, and increased resorption. Although the 
mechanisms underlying this phenomenon are still unclear, it is recognized that osteocyte 
apoptosis precedes temporally and spatially osteoclastic resorption. Induction of osteocyte 
apoptosis by injecting diphtheria toxin to transgenic mice expressing the diphtheria toxin 
receptor in osteocytes is sufficient to increase osteoclasts and trigger resorption in the 
vicinity of dead osteocytes.93 Moreover, osteocyte death is accompanied by increased 
osteoclasts in nearby bone in rodent models of unloading, excessive mechanical forces, or 
ovariectomy, opening the possibility that increased osteocyte apoptosis is a generalized 
mechanism to induce localized bone resorption.
One of the potential mechanisms by which increased osteocyte apoptosis could trigger local 
bone resorption is by increasing RANKL expression in osteocytes located close to dying 
cells. This notion is supported by the fact that inhibition of apoptosis by administering anti-
apoptotic bisphosphonates or caspase inhibitors blocks the increase in osteocytic RANKL 
found in the above described animal models.90–92, 94, 95 Further, deletion of RANKL from 
osteocytes and mature osteoblasts prevents the decrease in bone mass and the increase in 
osteoclast number in tail-suspended mice.82 Moreover, inhibition of osteocyte/osteoblast 
apoptosis with a bisphosphonate that does not affect osteoclasts or with a pan caspase 
inhibitor prevented the increase in osteocytic RANKL induced by unloading.94 However, the 
bisphosphonate did not prevent the loss of bone94 whereas the caspase inhibitor did.95 
Nevertheless, these findings demonstrate a cause-effect relationship between osteocyte 
apoptosis and osteocytic RANKL and suggest that at least under certain unloading 
conditions osteocytic RANKL is central for osteoclast formation and bone resorption.
In addition to osteocytic genes or pathways that regulate either bone formation or bone 
resorption, genetic manipulations targeting osteocytes can simultaneously control both arms 
of remodelling. For example, activation of βcatenin in osteocytes increases bone mass in the 
context of elevated bone formation and bone resorption, leading to high bone remodeling 
with bone gain.76 This effect contrasts with the findings that activation of βcatenin in 
osteoblasts/osteocytes increases bone mass due to reduced bone resorption, without affecting 
osteoblast function.89
INTEGRATION OF BONE MECHANICAL AND HORMONAL STIMULI BY 
OSTEOCYTES
Due to their strategic location, osteocytes have been long considered the ideal cells to 
mediate bone adaptation to changes in the mechanical environment; and extensive evidence 
accumulated during the past several decades revealed several mechanisms potentially 
involved in this phenomenon. Changes in mechanical force profoundly affect the viability of 
osteocytes (as mentioned when discussing the role of osteocytes on bone resorption). 
Further, mechanical stimulation alters the expression of osteocytic genes and induces the 
release of small molecules, which, in turn, regulate the generation and function of 
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osteoblasts and osteoclasts, thus impacting bone modeling and remodeling. Osteocytes are 
also target cells of the action of systemic hormones; which activate similar as well as 
different pathways than mechanical stimuli (Figure 5). There is also crosstalk between 
hormonal and mechanical signaling in osteocytes demonstrated by modulation of mechano-
responses by systemic hormones or by changes in the expression of hormone receptors.
Regulation of osteocyte lifespan by mechanical signals
Lack of mechanical stimulation, as with immobilization or paralysis, decreases bone mass 
and increases the risk of fractures. This is associated with high prevalence of osteocyte 
apoptosis in mice and rats in vivo.96, 97 Conversely, increasing levels of loading within the 
physiological range reduce the density of apoptotic osteocytes in rat ulnae.98
The elevation of osteocyte apoptosis with unloading might be due to the absence of survival 
signals provided by normal physical activity. Indeed, in vitro mechanical stimulation 
opposes the action of several pro-apoptotic stimuli; and the combination of several 
mechanisms are likely to be involved in promoting survival.99 Integrin engagement and 
activation of the focal adhesion kinase (FAK) is induced by mechanical stimulation, 
followed by activation of the Src/MEK/ERK signaling cascade in vitro.100 Furthermore, 
nuclear accumulation of the ERK survival kinase as well as ERK-mediated gene 
transcription are required for anti-apoptosis. In vivo studies showed that integrins are 
involved in the attachment of osteocytes to the lacunar/canalicular wall.101, 102 Moreover, 
deletion of β1 integrin from osteocytes results in abnormal response to unloading,103 adding 
support to a role of integrins in mechanotransduction.
The canonical Wnt/βcatenin pathway is also activated by loading,104 in part due to 
decreased expression of the antagonists of the pathway Dkk1 and sclerostin.8, 104 Because 
Wnts prevent apoptosis whereas the Wnt antagonists sFRP1 and sclerostin induce apoptosis 
in cultured osteocytic and osteoblastic cells,63, 105, 106 activation of this pathway could 
contribute to the maintenance of osteocyte/osteoblast survival with physiologic levels of 
loading. Further, βcatenin accumulation induced by mechanical stimulation is required for 
preventing glucocorticoid-induced osteocyte apoptosis in vitro,107, 108 suggesting that 
canonical Wnt signaling also promotes survival under pathological conditions. Moreover, in 
vivo activation of Wnt/βcatenin signaling, as in mice lacking the Wnt antagonist sFRP160 or 
expressing LRP5 activating mutations,109 leads to decreased prevalence of apoptotic 
osteocytes.
Mechanical stimulation of osteocytes also induces release of prostaglandin E2 (PGE2), 
produced by cyclooxygenase 2 (COX-2), an enzyme induced by mechanical stimulation.110 
Binding of PGE2 to the EP2 receptor and subsequent activation of cAMP/PKA and 
PI3K/Akt/βcatenin inhibits apoptosis of osteocytic cells induced by glucocorticoids.108
Some of these pro-survival pathways activated by loading in osteocytes have been also 
shown to be required for the anabolic effect induced by mechanical stimulation. Thus, mice 
lacking the Wnt co-receptor LRP5 or overexpressing Sost do not exhibit an anabolic 
response to loading,9, 111 and inhibition of prostaglandin synthesis blocks bone formation 
induced by mechanical stimulation.112
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Crosstalk between mechanical and hormonal signals in osteocytes
One example of a pro-survival pathway activated by mechanical stimuli that is also involved 
in hormonal responses is Src/ERK signaling, which is activated by mechanical stimulation 
downstream of integrins/FAK and by estrogens/androgens through non-genotropic signaling 
mediated by extra-nuclear functions of the estrogen (ER) or androgen receptors.100, 113 
(Figure 5). ERα or ERβ also play a permissive role in mechanotransduction, as their 
presence in the osteocytic cell membrane within caveolae is required for the ERK-mediated 
survival effect of mechanical stimulation in a ligand independent fashion.114 In addition, 
estrogen as well as mechanical stimulation induce ERα phosphorylation in ERK- and PKA- 
dependent manner.115 Consistent with these in vitro findings, mice lacking ERα or ERβ 
exhibit a reduced anabolic response to loading.116, 117
Like mechanical stimulation, systemic elevation of PTH reduces the expression of Sost/
sclerostin, which might contribute to the increase in bone formation by the hormone.91, 118 
Consistent with this notion, the increase in bone mass and in bone formation exhibited by 
transgenic mice expressing an activated PTHR1 in osteocytes is abrogated by Sost 
overexpression.12 Moreover, PTH signaling might interplay with mechanotransduction, as 
the anabolic response to mechanical stimulation is enhanced when PTH is administered 
together with loading119–122 and is decreased in parathyroidectomized rats.119 In addition, 
the increase in cancellous bone volume and improvement of mechanical properties induced 
by exercise is abolished when activation of the PTHR1 is inhibited using PTH(7-34) in mice.
123
 The effect of PTH in combination with mechanical stimulation is blocked by verapamil,
124
 suggesting the involvement of L-type voltage channels in the synergistic effect between 
the hormone and loading.
PTHR1 can also be activated by binding of the other ligand of this receptor, PTH related 
peptide (PTHrP). PTHrP expression is increased by mechanical stimulation in osteocytic and 
osteoblastic cells,125, 126 and the anti-apoptotic effect of mechanical stimulation is mimicked 
by treatment with PTHrP and abolished by silencing PTHR1 in vitro.126, 127 PTHrP, as PTH, 
decreases Sost expression in vitro in primary cultures of osteoblastic cells containing 
osteocytes.13 Taken together, this evidence strongly suggests that local increases in PTHrP 
induced by mechanical loading could contribute to maintaining osteocyte survival and to the 
anabolic action of mechanical loading.
In contrast to the overlapping and potentially synergistic signaling activated by mechanical 
signals and sex steroids or PTH, glucocorticoids antagonize survival and bone-maintaining 
signaling activated by mechanical stimulation. Glucocorticoids induce osteocyte and 
osteoblast apoptosis in vitro and in vivo in mice and humans, thus opposing the survival 
effect of mechanical stimuli on these cells.99, 128–132 Glucocorticoids inhibit whereas 
mechanical stimulation increases Wnt/βcatenin signaling. Further, whereas mechanical 
stimulation activates the FAK/ERK survival pathway, glucocorticoids-induced apoptosis is 
preceded by cell detachment (known as anoikis) through the activation of the FAK-related 
kinase Pyk2, and the kinase JNK.100, 133 The findings that glucocorticoids oppose the 
FAK/ERK pathway through activation of Pyk2 raise the possibility that Pyk2 could be 
inhibited to increase the mechanoresponsive FAK signaling. Indeed, a Pyk2 inhibitor has 
been shown to increase bone mass in rodents through stimulation of bone formation and 
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inhibition of bone resorption.134, 135 In addition, part of the pro-apoptotic actions of 
glucocorticoids on osteocytes and osteoblasts is mediate through endoplasmic reticulum 
(ER) stress, and inhibition of eIF2α dephosphorylation, which leads to ER stress, prevents 
apoptosis and the loss of bone mass induced by glucocorticoid excess in mice.136
Elevation of endogenous glucocorticoids may contribute to the effect of reduced mechanical 
stimulation, as evidenced by delayed increase in osteoblast apoptosis, and in the reduction of 
serum osteocalcin and vertebral strength in mice expressing the glucocorticoid-inactivating 
enzyme 11-β hydroxysteroid dehydrogenase in osteoblastic cells (OG2-11-β HSD2 mice) 
and subject to tail suspension.96 On the other hand, osteocytes still exhibit apoptosis in tail-
suspended OG2-11-β HSD2 mice indicating that the effect of unloading on osteocytes is not 
a consequence of increased endogenous glucocorticoids, but is entirely caused by reduced 
mechanical loading.
OSTEOCYTIC SIGNALING PATHWAYS AS THERAPEUTIC TARGETS
Our increased understanding of mechanosensory pathways provide opportunities of 
developing therapeutic approaches to improve bone health (Figure 5).
Agents that prevent osteocyte apoptosis preserve bone strength.137 Such is the case of 
bisphosphonates, which their anti-fracture efficacy cannot be completely explained by the 
effect of the drugs on bone mass. Bisphosphonates prevent osteocyte apoptosis induced by 
glucocorticoid excess and lack of mechanical forces, and this effect does not require the anti-
catabolic activity of the drugs, as it is exerted by bisphosphonates that inhibit apoptosis of 
osteoblastic cells but do not affect osteoclast function.94, 129, 138 Estrogens and androgens 
have also been shown to preserve osteocyte viability, and removal of sex steroids increase 
osteocyte apoptosis.113, 139 In addition, intermittent PTH administration decreases osteocyte 
apoptosis and increases osteocyte density.140, 141 Activation of Wnt/βcatenin signaling either 
by blocking inhibitors of the pathway directly or through mechanical stimulation, or as a 
consequence of PTH administration, promotes osteocyte survival.108, 118, 142, 143 Further, 
inhibition of osteocyte apoptosis with caspase inhibitors decreases resorption following 
fatigue loading or ovariectomy-induced thinning of cortical bone,92 and prevent the increase 
in bone resorption and the loss of bone induced by immobilization in the appendicular 
skeleton.95 These pieces of evidence support the possibility that by preventing osteocyte 
(and osteoblast) apoptosis, bone mass can be maintained and the effect of deleterious stimuli 
on bone can be at least in part neutralized.
Several ways of activating Wnt/βcatenin signaling by blocking antagonists of the pathway 
through pharmacologic interventions have been designed. Studies using humanized 
neutralizing anti-Dkk1 increase bone mass in growing female mice and in ovariectomized 
adult rhesus monkeys.144, 145 In addition, a small molecule inhibitor of sFRP1 increases 
bone volume in calvaria organ cultures.146 Further, inhibition of GSK3β thus stabilizing β-
catenin and activating canonical Wnt signaling, protects bone integrity, as shown in 
preclinical studies as well as in epidemiologic studies in which the GSK3β inhibitor lithium 
chloride was used to treat psychological disorders.60 However, since the Wnt pathway is 
active in numerous tissues and both Dkk1 and sFRP1 are widely expressed, the use of these 
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inhibitors might need to be restricted to local bone applications, to avoid unwanted effects in 
other organs. Nevertheless, anti-Dkk1 antibodies are currently being tested for the treatment 
of skeletal complications of multiple myeloma.147
More recently, a neutralizing antibody directed to Sost/sclerostin was developed. Sclerostin 
expression is restricted to osteocytes among bone cells and genetic increase in Sost 
expression leads to an almost exclusive bone phenotype. This makes sclerostin an excellent 
target to improve bone health without affecting other tissues. Preclinical studies showed that 
inhibition of sclerostin using the antibody prevents the decrease in bone mass induced by 
ovariectomy, excess glucocorticoid administration, ulcerative colitis, immobilization, and 
aging.148 Phase 2 studies have been carried out and show increased bone mineral density, 
increased bone formation and inhibition of resorption induced by treatment with the anti-
sclerostin antibody.149
Sclerostin protein was also detected in chondrocytes150–152 raising the possibility that 
treatment with the anti-sclerostin antibody has an impact in cartilage. In fact, deletion of 
Sost in mice worsens the osteoarthritic phenotype induced by medial meniscus 
destabilization.153 However, no difference in the development of age-dependent 
osteoarthritis was found between wild type and Sost KO mice.152 Moreover, intraarticular 
administration of an anti-sclerostin antibody did not alter the osteoarthritic phenotype 
induced by medial meniscus destabilization in rats;152 and no adverse osteoarthritic events 
have been reported in the human trials with anti-sclerostin antibodies.154 Overall, these 
studies suggest that even when sclerostin is expressed in cartilage, neutralization of its 
activity might not significantly affect the functionality of this tissue.
Recent studies have shown that administration of an inactivating FGF23 antibody reversed 
the hypophosphatemia and increased 1,25(OH)2 vitamin D levels in patients with XLH.155 
The antibody also increased circulating markers of bone formation, suggesting an 
improvement in bone mineralization. Consistent with this possibility, administration of the 
anti-FGF23 antibody improved mineralization in adult hyp mice, a murine model of XLH.
156
 Furthermore, a pan-specific FGF receptor inhibitor reversed the abnormal serum levels 
of phosphate, calcium, PTH and 1,25(OH)2 vitamin D, and improved the skeletal 
manifestations of hypophosphatemia in hyp mice, as well as in mice lacking DMP1, a model 
of ARHR.157
Attempts were made over the years to block osteoclast differentiation and therefore, to 
reduce bone loss, by targeting the RANKL/RANK/OPG signaling pathway.158–160 Because 
the current evidence suggest that osteocytes are one of the sources of RANKL and OPG in 
bone, therapeutic approaches modulating this pathway are examples of the potential benefits 
of targeting osteocytes to improve skeletal health.
PGE2 has a bone anabolic effect when administered in an intermittent fashion.161 However, 
due to the widespread systemic distribution and the side effects associated with PGE2 
administration, it is not used currently in the clinic. PGE2 acts in bone through the activation 
of the EP2 and EP4 receptors. Deletion of EP4 results in osteopenia in mice, with increased 
osteoclasts and decreased bone formation.162 EP4 agonists have been developed and were 
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shown to stimulate bone formation and inhibit bone resorption in ovariectomized rats.163 To 
avoid the systemic effect of activation of the receptor, a bisphosphonate-conjugated agonist 
was developed for bone targeting.164 The EP4 agonist-bisphosphonate conjugate increased 
bone formation and improved bone strength in ovariectomized rats. The levels of EP2, the 
other PGE2 receptor expressed in bone, is increased by mechanical stimulation and is 
involved in the effects of PGE2 on osteocytic cells upon mechanical stimulation in vitro.37 
Further, deletion of EP2 receptor in mice results in impaired osteoclastogenesis and 
decreased bone strength.165 EP2 agonists have been developed and induce periosteal bone 
formation upon local administration in rats. Whether activation of the receptor in osteocytes 
contribute to the effect of the EP agonists remains unknown.
Conclusions and future directions
Over the last two decades, our understanding of the function of osteocytes both as regulators 
of the activity of bone forming and resorbing cells and as modulators of the function of other 
tissues has markedly increased. Human mutations and experimental models have uncovered 
novel signaling pathways activated in osteocytes that can be targeted with therapeutic goals 
to improve bone health. Further, it is also now apparent that some stimuli that affect 
osteocytes and other bone cells affect skeletal muscle and vice versa. In particular, 
mechanical stimulation is required for maintaining both bone and muscle homeostasis. Thus, 
the crosstalk between the two tissues might be exploited in the future to provide 
opportunities for the combined of musculoskeletal integrity as a whole.
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Figure 1. Osteocyte and the hierarchic organization of bone
(A) X-ray image of a murine femur and (B) rat femur stained with von Kossa and McNeal to 
show the bone stained in black and bone marrow, stained in blue, showing the bone 
structure. (C) Image of dry human showing osteocytes and their canaliculi (in black). (D) 
Scanning electron microscopy of acid etched murine vertebral bone the cellular organization 
of osteocytes within bone with their projections reaching other osteocytes and cells on the 
bone marrow. (E) TRAP-stained osteoclasts (in red) on rat bone sections stained with 
TRAPase and toluidine blue and (F) osteoblasts present on bone surfaces covered by osteoid 
in rat bone sections stained with von Kossa and McNeal, showing the close proximity of 
osteocytes (grey arrows) to osteoblasts (red arrows) and osteoclasts (yellow arrows) on the 
bone surface. (G) Early osteocyte being embedded in bone matrix that is partially (left) and 
completely (right) mineralized (10,000 x). The boxes in panels B and F delineate the areas 
enlarged in panels C and F, respectively. Pictures for panels B and F were contributed by 
Keith Condon, Indiana University School of Medicine, Indianapolis, IN, USA. Picture for 
panel G was provided by Stephen B. Doty, Hospital for Special Surgery, New York, NY, 
USA.
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Figure 2. Molecular signature of osteocytes
The pattern of gene expression, changes as osteoblasts become embedded in the bone matrix 
and differentiate into osteocytes. The function of the different proteins is also shown. > 
indicate higher expression in these cells, compared to other cells of the osteoblast lineage.
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Figure 3. Role of osteocytic genes in the regulation of mineral metabolism
Osteocytes control bone mineralization and the levels of phosphate in the circulation by 
producing proteins that act locally on bone cells or as endocrine hormones in kidney.
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Figure 4. Osteocytes as regulators of bone formation and resorption
Osteocytes produce and secrete molecules that stimulate or inhibit osteoclast or osteoblast 
differentiation, viability, and function.
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Figure 5. Osteocytic signaling pathways as therapeutic targets
Therapeutic approaches (green lines and text) take advantage of pathways activated by 
mechanical and hormonal stimuli in osteocytes (blue lines and text). Ab, antibody.
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